Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab - Wikidata - awgldk - TriplyDB

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab

http://www.wikidata.org/entity/Q34855776

about

Cardiac toxicity of trastuzumab in elderly patients with breast cancer The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy Cardio-oncology: Concepts and practice C-Reactive Protein and Breast Cancer: New Insights from Old Molecule Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level Evaluation and management of patients with heart disease and cancer: cardio-oncology Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Twenty years of anti-HER2 therapy-associated cardiotoxicity Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care.Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients Cardiovascular disease after cancer therapy.An update on cardio-oncology.A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma.Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors.Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Roadmap for biomarkers of cancer therapy cardiotoxicity.Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer.Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.Cardiovascular prevention in the cancer survivor.Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.Anthracycline-Induced Cardiomyopathy in Adults.The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.Identifying cancer patients at risk for cardiotoxicity.Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers.Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.Chemotherapy-induced cardiomyopathy.

P2860

Q26741182-BEFB1B87-DD66-4B45-89DF-87D9F68A8B5A Q26743433-1604B10B-C01C-4429-B012-8C1D661F8BD9 Q26750878-150CF0E0-ABBD-4074-868F-DC5B44BFAAE0 Q26773592-813B1CDF-508C-45BD-8626-9E96E2C7694F Q26785410-7E298930-E1F8-4375-81A7-9E7CD7DD8598 Q26864094-5FAED2F7-998C-45F4-8022-376CE9D3E3CD Q26998273-19459A1D-32D8-4B0B-A5FF-9F27241C1645 Q27007849-1CD32860-9969-4305-9028-31462C15D1C1 Q27027354-C4FCAE44-0FD8-4296-A0B2-51CB974CC95B Q28079391-B90A57CE-FFC7-4FC3-BFD4-AA42414EED11 Q28087776-C99FA6B7-F3DD-4B41-85F1-682148D56790 Q33565936-F5FF2D5D-A005-48FB-BBCA-6873D227FE7D Q33658456-EAB2D31E-CF7B-432C-A9A8-FA97DADF8476 Q33816471-DD848D9F-988C-45D4-AC90-376B3975CD60 Q34604429-2251D62C-FAD8-4B5A-8571-0A5482129E4E Q34650059-314A3BDC-48C2-430D-AD8D-DCA6F7700B6E Q35139516-BB4E3756-B957-437C-B975-F8F5B1B9616C Q35588736-FF0E0677-654A-4367-AF56-07DD0BC9977D Q35774310-17355384-10B2-456A-A6CD-4D9A8DB9A86B Q35915714-1F64A6DB-3DDB-4930-9671-E00671231599 Q36038613-F3E9C244-E0AF-4A2F-B233-ECF9597C953C Q36181301-E2C79514-213A-4386-A6AA-4AA261DF2D44 Q36339976-7754293A-2355-4377-8E59-24903FE88EC7 Q36451899-A69D12EF-A0BE-4DE0-891B-A7DB23755643 Q36626934-3DF25F73-EE87-47E1-98BB-A5183889C921 Q36788268-2928F836-A9FC-444D-BD0B-998FCC94C2EA Q37158620-89555E6B-E57E-4F44-9920-53F845621875 Q37190433-1ADA2C32-0475-4D15-B52D-C163B00F723C Q37311943-536C8FB5-CB3C-4009-9568-68844E1128AB Q37314505-0DBF186B-476A-4DFC-BB6B-C4D418087E43 Q37560059-93C276E0-2388-4161-A62D-71F00E1A75EC Q38338228-8CF9E6C4-113F-4F21-8927-6FA88E049162 Q38362383-72056AA9-8F8C-4D83-81B1-B35253CC8722 Q38508938-BBDC1A0F-ADD0-4F98-9EF8-9AD09A01B740 Q38542462-7EA94FD0-E3C4-44B5-A188-EC33D7C05F28 Q38551693-BF4722FD-C2B6-4BCA-95A1-6E893149E6CD Q38551772-1F404678-A79A-4128-9CCE-2165346F3C53 Q38551776-EDC51AFD-A5BE-4CE5-9F83-B4336FF967DB Q38559474-F8A39416-CFB5-4B25-B465-A6198F0A9385 Q38580452-6B034C81-D42A-4ADF-9317-473C6182BE50

P2860

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab

http://www.wikidata.org/entity/Q34855776

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@ast

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@en

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@nl

type

label

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@ast

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@en

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@nl

prefLabel

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@ast

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@en

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@nl

P1433

Q34855776-2BFC6CCE-0E06-4D6E-8ACF-A60E759CBE7B

P1476

Q34855776-E8B98524-2608-44C1-90B0-6540F54F473B

P2093

Q34855776-039299BF-DDD7-4D63-BBD5-6022334BA97D

Q34855776-19691883-EE24-4D8E-821E-431C087812E4

Q34855776-3E77C2E9-DA09-4DE1-879B-1A736973E850

Q34855776-449FD257-6B30-49BE-A681-67E72749542D

Q34855776-4A1ABFA2-A960-4CAF-8962-871B4840FE13

Q34855776-51C5B4A4-0EA6-4AC7-89CB-60467F8278E5

Q34855776-53CA68E8-4B3C-4BBC-96AF-404AA81F06FC

Q34855776-5CE8FDDA-BB24-4285-BBDA-9E1A7803A241

Q34855776-5FED012E-7A32-459A-83CD-90896969091A

Q34855776-83074A63-FABD-401F-83B8-519041A7BF62

P2860

Q34855776-03BB27F5-2804-4077-AD53-4382C1AA9A42

Q34855776-04E65919-2AEE-461C-9CFB-6206BA36144E

Q34855776-0BF3E769-458E-451D-944F-D95CA8359240

Q34855776-0E9C6FDC-0DEE-4928-B6AD-853F52AC24BC

Q34855776-10C303E1-A123-4EE2-8285-87F579ED4E0D

Q34855776-152E5254-E4AF-46DF-BC21-16A82B38A7A1

Q34855776-22F0EF56-FEB2-41F6-8DB0-5E47B221C16F

Q34855776-27502E3D-05DD-4659-9C25-EC57BC499E93

Q34855776-3E84F631-2721-4B23-8AC0-90C7A87B68B8

Q34855776-4BA70832-E100-4D6E-9A9E-0A5310B5A114

P304

Q34855776-A729CACE-1AA8-477E-9771-32FB0BEA67A7

P31

Q34855776-924FF7CA-D826-48BA-927E-8B195E676196

P356

Q34855776-470D3C42-7FA3-4C41-A23C-2101B02F6422

P407

Q34855776-F7DB37A7-558E-4B56-8AB4-B1BA794F0856

P433

Q34855776-36F3BB81-B05B-423C-B62E-06E9DB0E2BF2

P478

Q34855776-5F7A31BB-2211-485C-A847-D78D1D920880

P50

Q34855776-4B2ACFBC-F648-46A5-B2ED-D159B0A5F892

P577

Q34855776-9BD26702-FD9D-4014-93C2-ACE75ADBCECD

P698

Q34855776-63E3DE6C-2AAD-455C-A615-4B2117018B72

P921

Q34855776-49F1ECB1-76DA-4A64-B028-F72129246D53

Q34855776-E5D21704-3058-4761-9B8F-CFC3EBEFF073

P932

Q34855776-20B15A03-6690-44AE-8CD6-0E6D115BE31A

P356

J.JACC.2013.10.061

P1433

Journal of the American College of Cardiology

P1476

Early increases in multiple bi ...... icin, taxanes, and trastuzumab

@en

P2093

Benjamin French

http://www.w3.org/2001/XMLSchema#string

Bonnie Ky

http://www.w3.org/2001/XMLSchema#string

Elkan F Halpern

http://www.w3.org/2001/XMLSchema#string

Heloisa Sawaya

http://www.w3.org/2001/XMLSchema#string

Igal A Sebag

http://www.w3.org/2001/XMLSchema#string

Irene Kuter

http://www.w3.org/2001/XMLSchema#string

Jonathan Passeri

http://www.w3.org/2001/XMLSchema#string

Jose Banchs

http://www.w3.org/2001/XMLSchema#string

Joseph R Carver

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Plana

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac dysfunction in the trastuzumab clinical trials experience

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes

Biomarkers in heart failure

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Adjuvant trastuzumab in HER2-positive breast cancer.

Multiple biomarkers for risk prediction in chronic heart failure.

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

P304

809-816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2013.10.061

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

James L Januzzi

P577

2013-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24291281

http://www.w3.org/2001/XMLSchema#string

P921

P932

4286181

http://www.w3.org/2001/XMLSchema#string